According to the Complaint, Osiris Therapeutics, Inc. researches, develops, manufactures and commercializes regenerative medicine products.

On March 12, 2019, Osiris issued a press release announcing the Proposed Transaction. Pursuant to the Merger Agreement: (i) Papyrus Acquisition Corp. will merge with and into Osiris, and (ii) Osiris shall continue as the surviving corporation in the Merger.

The Complaint alleges that the Defendants misrepresented or omitted material information concerning the Proposed Transaction in the Proxy, in violation of Section 14(d) of the Exchange Act.

This case was voluntarily dismissed as moot on May 14, 2019.